NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug may halt devastating NMOSD attacks faster
Disease control OngoingThis study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specif…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising NMOSD attack treatment trial pulled before it began
Disease control TerminatedThis study aimed to test the drug eculizumab for people having an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the central nervous system. The trial planned to give four weekly doses of eculizumab alongside standard s…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC